Evidence map›Paper›PMID 39285158›Full record

ArticleNature communications2024

Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation.

Sjors P A van der Lans, Bart W Bardoel, Maartje Ruyken, Carla J C de Haas, Stan Baijens, Remy M Muts, Lisette M Scheepmaker, Piet C Aerts, Marije F L van 't Wout, Johannes Preiner and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The acquisition ofmBio · 2026
    Article
  6. Article
  7. Article
  8. The acquisition ofbioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. O-antigen polysaccharides inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sjors P A van der Lans *Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Bart W Bardoel *Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-6450-277X
Maartje RuykenMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Carla J C de HaasMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Stan BaijensMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0009-0009-3045-5763
Remy M MutsMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-4325-1382
Lisette M ScheepmakerMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Piet C AertsMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Marije F L van 't WoutMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0009-0008-5507-541X
Johannes PreinerUniversity of Applied Sciences Upper Austria, Linz, Austria.ORCID 0000-0002-6755-6543
Renoud J MarijnissenGenmab, Utrecht, The Netherlands.ORCID 0000-0002-6836-675X
Janine SchuurmanGenmab, Utrecht, The Netherlands.ORCID 0000-0002-9738-9926
Frank J BeurskensGenmab, Utrecht, The Netherlands.
Priscilla F KerkmanMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-6212-002X
Suzan H M RooijakkersMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. s.h.m.rooijakkers@umcutrecht.nl.ORCID 0000-0003-4102-0377

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101001937Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) 16442
6 · The paper itself

Abstract

Antibody-dependent complement activation plays a key role in the natural human immune response to infections. Currently, the understanding of which antibody-antigen combinations drive a potent complement response on bacteria is limited. Here, we develop an antigen-agnostic approach to stain and single-cell sort human IgG memory B cells recognizing intact bacterial cells, keeping surface antigens in their natural context. With this method we successfully identified 29 antibodies against K. pneumoniae, a dominant cause of hospital-acquired infections with increasing antibiotic resistance. Combining genetic tools and functional analyses, we reveal that the capacity of antibodies to activate complement on K. pneumoniae critically depends on their antigenic target. Furthermore, we find that antibody combinations can synergistically activate complement on K. pneumoniae by strengthening each other's binding in an Fc-independent manner. Understanding the molecular basis of effective complement activation by antibody combinations to mimic a polyclonal response could accelerate the development of antibody-based therapies against problematic infections.

Indexed as

Antibodies, BacterialComplement ActivationImmunoglobulin GKlebsiella pneumoniaeB-LymphocytesHumansMemory B CellsAntibodies, BacterialImmunoglobulin G

Identifiers

PMID39285158
PMCPMC11405761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.